Neurocrine nears $2.5 billion deal for Soleno Therapeutics, FT reports
06/04/2026 03:55
Fixes syntax in paragraph 1 April 5 (Reuters) - Drugmaker Neurocrine Biosciences NBIX.O is nearing a more than $2.5 billion acquisition of Soleno Therapeutics SLNO.O, the Financial Times reported on Sunday. Reuters could not immediately confirm the report. (Reporting by Gnaneshwar Rajan in Bengaluru; Editing by Sumana Nandy) ((Gnaneshwar.Rajan@thomsonreuters.com;))
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall